Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1066 | 1066 | 1067 | 1095 | 1422 | 2304 |
Fund Return | 6.57% | 6.57% | 6.73% | 3.08% | 7.3% | 8.7% |
Place in category | 170 | 170 | 238 | 254 | 84 | 4 |
% in Category | 26 | 26 | 40 | 45 | 20 | 2 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Pictet CH Institutional Swiss EquiI | 1.53B | 6.08 | 2.73 | 7.19 | ||
Pictet CH Institutional Swiss EquiP | 1.53B | 6.02 | 2.53 | 6.98 | ||
Pictet CH Institutional Swiss EquZD | 1.53B | 6.20 | 3.22 | 7.69 | ||
Pictet CH Institutional Swiss EquiZ | 1.53B | 2.66 | 4.28 | 7.37 | ||
Pictet CH Institutional Swiss EquID | 1.53B | 2.58 | 3.78 | 6.87 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
CH0033782431 | 2.35B | 6.76 | 5.03 | 6.69 | ||
Raiffeisen Futura Swiss Stock A | 2.07B | 2.12 | 2.41 | 6.12 | ||
UBS CH Equity Fund Swiss Income CHF | 2.01B | 2.43 | 3.56 | 5.81 | ||
UBS CH Equity Fund Swiss Income CHQ | 2.01B | 2.59 | 4.20 | 6.41 | ||
UBAM Swiss Equity AD CHF Inc | 1.72B | 7.99 | -0.55 | 5.90 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Nestle | CH0038863350 | 13.82 | 92.70 | +0.67% | |
Roche Holding Participation | CH0012032048 | 9.98 | 221.00 | +1.01% | |
Novartis | CH0012005267 | 9.60 | 89.50 | -0.56% | |
Richemont | CH0210483332 | 7.29 | 129.85 | +1.64% | |
Zurich Insurance Group | CH0011075394 | 6.21 | 439.90 | -0.61% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Buy | Buy | Buy |
Technical Indicators | BUY | Strong Buy | Strong Buy |
Summary | Buy | Strong Buy | Strong Buy |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review